Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    "Myeloid sarcoma"
Show Display Options
Rank Status Study
1 Recruiting Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
Interventions: Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion
2 Recruiting Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Myeloid Sarcoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
Interventions: Drug: Cytarabine;   Drug: Vosaroxin
3 Terminated
Has Results
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myelogenous Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: G-CSF;   Biological: Interleukin-2;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Biological: Natural killer cell therapy;   Biological: T-cell depleted HPC transplant;   Biological: CD45RA-depleted HPC transplant
4 Recruiting Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Leukemia Cutis;   Myeloid Sarcoma;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
Interventions: Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
5 Recruiting CIP-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Conditions: Granulocytic Sarcoma;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: 6,8-Bis(benzylthio)octanoic Acid;   Drug: Cytarabine;   Procedure: Hematopoietic Cell Transplantation;   Drug: Mitoxantrone Hydrochloride
6 Completed PET-CT in AML for Detection of Extramedullary AML Manifestations
Condition: Newly Diagnosed or Relapsed Acute Myeloid Leukemia
Intervention:

Indicates status has not been verified in more than two years